|
WO2021078910A1
|
|
Immunotherapy targeting tumor neoantigenic peptides
|
|
WO2021043804A1
|
|
Immunotherapy targeting tumor neoantigenic peptides
|
|
JP2020169194A
|
|
Method for preparing viral particles with cyclic dinucleotide and use of the particles for treating cancer
|
|
WO2020245321A1
|
|
METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
|
|
WO2020216898A1
|
|
Biomarkers for predicting resistance to cancer drugs
|
|
WO2020201095A1
|
|
Interleukin-2 variants with modified biological activity
|
|
WO2020183011A1
|
|
Htr1d inhibitors and uses thereof in the treatment of cancer
|
|
CA3112044A1
|
|
Use of long non-coding rna for the diagnosis of prostate cancer
|
|
WO2020002197A1
|
|
Method of inducing or preventing the merging of droplets
|
|
EP3802522A1
|
|
Compounds with biguanidyl radical and uses thereof
|
|
US2020405853A1
|
|
Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
|
|
EP3697809A1
|
|
Dap10/12 based cars adapted for rush
|
|
WO2019077164A1
|
|
Hook fusion protein for regulating the cellular trafficking of a target protein
|
|
EP3684410A1
|
|
Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
|
|
WO2019020728A1
|
|
New subpopulations of cancer associated fibroblasts as prognosis markers for immunotherapy treatments
|
|
WO2019011971A1
|
|
Method for detecting a mutation in a microsatellite sequence
|
|
CN111032025A
|
|
Use of an inhibitor of SUV39H1 histone methyltransferase in the combination therapy of cancer
|
|
KR20200027512A
|
|
Immune cells defective in SUV39H1
|
|
US2019367635A1
|
|
Anti-LSP1 antibody
|
|
CA3031327A1
|
|
Device for adsorbing odours
|
